Immunotherapy Drug Helping Lung Cancer Patients

The immunotherapy drug Tecentriq (atezolizumab) was accepted earlier this 12 months by the U.S. Foodstuff and Drug Administration to deal with patients with newly diagnosed non-tiny mobile lung cancers (NSCLC), which comprise up to eighty five% of all lung tumors.